E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
advanced/metastatic squamous non small cell lung cancer |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029522 |
E.1.2 | Term | Non-small cell lung cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029521 |
E.1.2 | Term | Non-small cell lung cancer stage IIIB |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10059515 |
E.1.2 | Term | Non-small cell lung cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10001254 |
E.1.2 | Term | Adenosquamous cell lung cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001253 |
E.1.2 | Term | Adenosquamous cell lung cancer stage IIIB |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
For phase Ib:
To determine the maximum-tolerated dose (MTD) / recommended Phase II dose (RP2D) of buparlisib when administered orally in combination with every-3-week administration of docetaxel to adult patients with Stage IIIb or Stage IV NSCLC of squamous histology previously treated with platinum-based chemotherapy
For phase II:
To estimate the treatment effect of every-three-week administration of docetaxel and daily buparlisib or placebo on PFS in patients previously treated with platinum-based chemotherapy for advanced or metastatic squamous NSCLC |
|
E.2.2 | Secondary objectives of the trial |
For phase Ib:
- Assess safety and tolerability
- Assess preliminary activity
For phase II:
- Assess safety and tolerability
- Assess additional efficacy parameters
- Understand the effect of docetaxel in combination with buparlisib or placebo on patients’ symptoms and health-related quality of life (HRQoL)
- Investigation of the PK of both buparlisib and docetaxel when administered in combination |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Patient is an adult ≥ 18 years old at the time of informed consent
•Patient has histologically and/or cytologically confirmed diagnosis of squamous NSCLC. Diagnosis of mixed squamous and non-squamous or adenosquamous NSCLC will be acceptable for enrollment.
•Patient has received one prior approved regimen of platinum-based chemotherapy (excluding a docetaxel-containing regimen) for advanced or metastatic (Stage IIIb or Stage IV) squamous NSCLC, followed by disease progression. A drug provided as maintenance therapy following cytotoxic chemotherapy will be considered to be part of that regimen.
Note: Patients who received paclitaxel therapy are eligible for this trial.
•Patient has adequate tumor tissue (either archival or new tumor biopsy) for the analysis of PI3K-related biomarkers.
- Enrollment in the Phase II part of the study is contingent on the central laboratory confirming receipt of an adequate amount of tissue including sufficient DNA for analysis.
•Patient has measurable or non-measurable disease according to RECIST version 1.1 criteria.
- Phase II only: Patient must have at least one measurable lesion as per RECIST criteria.
•Patient has an ECOG performance status ≤ 1
•Patient has adequate bone marrow and organ function
|
|
E.4 | Principal exclusion criteria |
•Patient has received previous treatment with a PI3K or AKT inhibitor
•Patient has symptomatic Central Nervous System (CNS) metastases
- Patients with asymptomatic CNS metastases may participate in this trial. The patient must have completed prior local treatment, if any, for CNS metastases ≥ 28 days prior to the start of study treatment (including radiotherapy and/or surgery, or ≥ 14 days for stereotactic radiosurgery).
•Patient has a score ≥ 12 on the PHQ-9 questionnaire.
•Patient selects a response of “1, 2 or 3” to question number 9 on the PHQ-9 questionnaire regarding potential for suicidal thoughts or ideation (independent of the total score of the PHQ-9).
•Patient has a GAD-7 mood scale score ≥ 15.
•Patient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation or patients with active severe personality disorders.
•Patient has ≥ CTCAE grade 3 anxiety |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1
- Progression Free Survival (PFS) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- Day 21 for incidence of DLT
- After 70 PFS events have been observed at 9 months after patient enrollment for PFS |
|
E.5.2 | Secondary end point(s) |
1. Number of patients with at least one adverse event
2. Number of patients with laboratory abnormalities
3. Overall Survival (OS)
4. Overall response rate (ORR)
5. Time to response (ToR)
6. Duration of response (DR)
7. Change in electrocardiogram (ECG) and cardiac imaging
8. Changes in vital signs
9. Shift in ECOG performance status
10. Change in Mood scales
11. Time to definitive 10% deterioration in the global health status/quality of life (QOL) scale score of the EORTC QLQ-C30
12. Change in the global health status/quality of life (QOL) scale score of the EORTC QLQ-C30
13. Docetaxel and buparlisib plasma concentrations
14. PFS Phase Ib) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Endpoints number:
1, 2, 7, 8 & 10: treatment start until 30 days after the last dose
3: : 8 months (Phase Ib) and from time of randomization to death (Phase II)
4: time from start date of study treatment in Phase Ib and from date of randomization in phase II to the date of first documented response
5: date of start of study treatment in Phase Ib and date of randomization in phase II to the date of first documented response
6: date of first documented response, the following date of event
9: Baseline, worst post-baseline result
11: date of randomization, date of event
12: baseline, at time of each assessment
13: cycle 1, end of treatment
14: start date of treatment, 3 months, date or progression or death |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 52 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Belgium |
Brazil |
Canada |
China |
Colombia |
France |
Germany |
Hong Kong |
Hungary |
Italy |
Japan |
Korea, Republic of |
Norway |
Poland |
Russian Federation |
Slovakia |
Spain |
Sweden |
Taiwan |
Thailand |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Phase Ib part:
All patients have discontinued treatment and have completed:
- 8 months survival follow up (in case phase II part is not initiated)
- 30 days safety follow up (in case phase II part is initiated)
Phase II part:
At the latest occurence of:
- at least 1 year has elapsed since the data cut off for primary analysis and all patients have completed the safety follow up
- at least 75% of deaths have been observed |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |